Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R, EMERALD-1 Investigators

Open source

DOI: 10.1016/s0140-6736(24)02551-0
Published: 2025 Jan 18
Container: Lancet (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-24-02551-0,
  title = {Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.},
  author = {Sangro B and Kudo M and Erinjeri JP and Qin S and Ren Z and Chan SL and Arai Y and Heo J and Mai A and Escobar J and Lopez Chuken YA and Yoon JH and Tak WY and Breder VV and Suttichaimongkol T and Bouattour M and Lin SM and Peron JM and Nguyen QT and Yan L and Chiu CF and Santos FA and Veluvolu A and Thungappa SC and Matos M and Żotkiewicz M and Udoye SI and Kurland JF and Cohen GJ and Lencioni R and EMERALD-1 Investigators},
  year = {2025},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(24)02551-0},
  url = {https://doi.org/10.1016/s0140-6736(24)02551-0}
}

RIS

TY  - JOUR
TI  - Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
AU  - Sangro B
AU  - Kudo M
AU  - Erinjeri JP
AU  - Qin S
AU  - Ren Z
AU  - Chan SL
AU  - Arai Y
AU  - Heo J
AU  - Mai A
AU  - Escobar J
AU  - Lopez Chuken YA
AU  - Yoon JH
AU  - Tak WY
AU  - Breder VV
AU  - Suttichaimongkol T
AU  - Bouattour M
AU  - Lin SM
AU  - Peron JM
AU  - Nguyen QT
AU  - Yan L
AU  - Chiu CF
AU  - Santos FA
AU  - Veluvolu A
AU  - Thungappa SC
AU  - Matos M
AU  - Żotkiewicz M
AU  - Udoye SI
AU  - Kurland JF
AU  - Cohen GJ
AU  - Lencioni R
AU  - EMERALD-1 Investigators
PY  - 2025
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(24)02551-0
UR  - https://doi.org/10.1016/s0140-6736(24)02551-0
ER  -

APA

B, S., M, K., JP, E., S, Q., Z, R., SL, C., Y, A., J, H., A, M., J, E., YA, L. C., JH, Y., WY, T., VV, B., T, S., M, B., SM, L., JM, P., QT, N., L, Y., CF, C., FA, S., A, V., SC, T., M, M., M, Ż., SI, U., JF, K., GJ, C., R, L., & Investigators, E. (2025). Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(24)02551-0

Source records

pubmed · retrieved 2026-09-26T12:32:41.532Z
europe-pmc · retrieved 2026-09-26T12:32:41.531Z